Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly.
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Haematology "L. and A. Seràgnoli" S. Orsola-Malpighi University Hospital, Bologna, Italy. francesca.palandri@unibo.it.
Francesca
F
Palandri
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Haematology "L. and A. Seràgnoli" S. Orsola-Malpighi University Hospital, Bologna, Italy.
Nicola
N
Polverelli
Department of Cellular Biotechnologies and Haematology, Sapienza University Rome, Rome, Italy.
Massimo
M
Breccia
Department of Haematology and Oncology, Città della Salute e della Scienza Hospital, Turin, Italy.
Barbara
B
Nicolino
Department of Haematology and Oncology, Città della Salute e della Scienza Hospital, Turin, Italy.
Umberto
U
Vitolo
Department of Cellular Biotechnologies and Haematology, Sapienza University Rome, Rome, Italy.
Giuliana
G
Alimena
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Haematology "L. and A. Seràgnoli" S. Orsola-Malpighi University Hospital, Bologna, Italy.
Michele
M
Cavo
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Haematology "L. and A. Seràgnoli" S. Orsola-Malpighi University Hospital, Bologna, Italy.
Nicola
N
Vianelli
Department of Haematology and Oncology, Città della Salute e della Scienza Hospital, Turin, Italy.
Giulia
G
Benevolo
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D009929:Organ Size; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000473:pathology; D011720:Pyrazoles / Q000819:agonists*; D011743:Pyrimidines; D013154:Spleen; D013163:Splenomegaly; D016896:Treatment Outcome
D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib
myelofibrosis; ruxolitinib; splenomegaly